Summary by Futu AI
HUTCHMED ANNOUNCED TODAY THAT MR. TU CHI KEUNG WILL RETIRE AS CHAIRMAN AND EXECUTIVE DIRECTOR AFTER 23 YEARS AT THE SERVICE COMPANY. THE COMPANY ALSO ANNOUNCED THAT DR. ELDER, WHO HAS BEEN A NON-EXECUTIVE DIRECTOR SINCE 2016, WILL TAKE OVER AS THE NEW CHAIRMAN. Dr. Elder has more than 30 years of global business leadership experience in biotech, healthcare, and more. Mr Tu Chi Keung said his retirement was to deal with private affairs and health care and would continue to contribute to the company as a strategic consultant to the company. Dr. Elder's appointment will take effect on May 17, 2024. WONG PHARMACEUTICALS IS A BIOMEDICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF TARGETED DRUGS AND IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES.